Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?

Key Takeaways DHR's Life Sciences segment's revenues are likely to drop 3.4% on weak demand in key end markets. Diagnostics performance is expected to be hurt by soft molecular test demand and lower China sales. Biotechnology revenues are projected to rise 7% on strong bioprocessing and discovery business demand.Danaher Corporation (DHR) is scheduled to release second-quarter 2025 results on July 22, before market open.The Zacks Consensus Estimate for revenues is pegged at $5.84 billion, which indicates a ...